• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.

作者信息

Hoffman Keith B, Demakas Andrea, Erdman Colin B, Dimbil Mo, Doraiswamy P Murali

出版信息

BMJ. 2013 Jul 23;347:f4656. doi: 10.1136/bmj.f4656.

DOI:10.1136/bmj.f4656
PMID:23881998
Abstract
摘要

相似文献

1
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.1999 - 2012年美国食品药品监督管理局不良事件报告系统中奥司他韦的神经精神不良反应
BMJ. 2013 Jul 23;347:f4656. doi: 10.1136/bmj.f4656.
2
Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment.接受奥司他韦治疗或未接受抗病毒治疗的流感患者发生神经精神不良事件的发生率。
Int J Clin Pract. 2009 Apr;63(4):596-605. doi: 10.1111/j.1742-1241.2009.02010.x.
3
Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.在自发不良事件报告中接受奥司他韦治疗患者的神经精神不良事件分析
Biol Pharm Bull. 2015;38(10):1638-44. doi: 10.1248/bpb.b15-00253.
4
Safety profile of oseltamivir during the 2009 influenza pandemic.奥司他韦在 2009 年流感大流行期间的安全性概况。
Pharmacoepidemiol Drug Saf. 2011 May;20(5):532-43. doi: 10.1002/pds.2136.
5
Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).抗精神病药物、血糖紊乱与危及生命的糖尿病事件：对美国食品药品监督管理局不良事件报告系统（1968 - 2004年）的贝叶斯数据挖掘分析
Ann Clin Psychiatry. 2008 Jan-Mar;20(1):21-31. doi: 10.1080/10401230701844612.
6
Oseltamivir- related psychiatric manifestations.
Actas Esp Psiquiatr. 2012 Jan-Feb;40(1):46-8. Epub 2012 Jan 1.
7
Oseltamivir for All: Should It Become an Over-the-Counter Medication for Influenza Treatment?
Pharmacotherapy. 2020 Mar;40(3):182-185. doi: 10.1002/phar.2370. Epub 2020 Feb 12.
8
FDA guidance document on monitoring delayed adverse events a good first start.
Mol Ther. 2005 Dec;12(6):991-2. doi: 10.1016/j.ymthe.2005.10.011. Epub 2005 Nov 3.
9
Postmarketing surveillance and reporting of adverse drug events.药品上市后监测及药品不良反应报告。
S D J Med. 2004 Jan;57(1):13-4.
10
US Food and Drug Administration: adverse event reporting.美国食品药品监督管理局：不良事件报告
CRNA. 1998 Nov;9(4):135-8.

引用本文的文献

1
Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance.与神经氨酸酶抑制剂相关的报告不良药物事件的患者特征分类：药物警戒中潜在类别分析的适用性研究。
Int J Clin Pharm. 2022 Dec;44(6):1332-1341. doi: 10.1007/s11096-022-01477-6. Epub 2022 Sep 26.
2
Identifying Acute Neuropsychiatric Events in Children and Adolescents.识别儿童和青少年的急性神经精神事件。
Hosp Pediatr. 2022 May 1;12(5):e152-e160. doi: 10.1542/hpeds.2021-006329.
3
COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.
COVID-19：正在研发中的抗病毒药物和酶抑制剂/受体阻滞剂。
Exp Biol Med (Maywood). 2021 Jul;246(13):1533-1540. doi: 10.1177/1535370221999989. Epub 2021 Mar 23.
4
The Rationale for Potential Pharmacotherapy of COVID-19.新型冠状病毒肺炎潜在药物治疗的基本原理
Pharmaceuticals (Basel). 2020 May 14;13(5):96. doi: 10.3390/ph13050096.
5
Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System.静脉镇静剂相关严重心血管不良事件报告：MedWatch不良事件报告系统的回顾性分析
Drugs Real World Outcomes. 2019 Sep;6(3):141-149. doi: 10.1007/s40801-019-00161-y.
6
Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report.奥司他韦诱发史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症——病例报告
Medicine (Baltimore). 2019 May;98(19):e15553. doi: 10.1097/MD.0000000000015553.
7
The Relationship Between Oseltamivir and Suicide in Pediatric Patients.奥司他韦与儿科患者自杀的关系。
Ann Fam Med. 2018 Mar;16(2):145-148. doi: 10.1370/afm.2183.
8
MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.MSBIS：一种多步骤生物医学信息学筛选方法，用于识别减轻甲氧氯普胺引起的迟发性运动障碍风险的药物。
EBioMedicine. 2017 Dec;26:132-137. doi: 10.1016/j.ebiom.2017.11.015. Epub 2017 Nov 22.
9
A travelling camper with a spiking fever, headache, myalgia, hepatitis, and intracellular inclusions.一名出现高热、头痛、肌痛、肝炎及细胞内包涵体的旅行露营者。
Lancet Infect Dis. 2017 Dec;17(12):1318. doi: 10.1016/S1473-3099(17)30305-5.
10
Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses and .十六烷基氯化吡啶（CPC）对流感病毒具有强大、快速的活性。
Pathog Immun. 2017;2(2):252-269. doi: 10.20411/pai.v2i2.200. Epub 2017 Jun 26.